Abstract:The synthesis and characterization of a gadolinium-based contrast agent conjugated with 3-phosphoglycerate (Gd-3PG) is reported. The synthetic steps are optimized to incorporate a selective deprotection strategy of a primary over secondary tert-butyl dimethyl silyl (TBS) hydroxyl. The relaxivity of Gd-3PG shows characteristic improvement, likely due to secondary sphere effects and/or an increase in molecular weight (5.39 ± 0.14 mM-1 s-1 at 1.4 T and 37 °C). Michaelis-Menten enzymatic kinetics were measured on the modified 3PG-arm and show similar activity to the native 3PG metabolite, Km = 240 ± 30 μM. This agent and future versions of this type of GBCA, which are conjugated to glycolytic metabolites, were designed to monitor in-vivo allosteric regulatory events in glycolytic processes.

Synthesis and Relaxivity of Gadolinium-Based DOTAGA Conjugated 3-Phosphoglycerate